Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Agios Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02074839
First received: February 21, 2014
Last updated: November 23, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2018
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)